Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. And joining me today is the President and CEO of Vertex Pharmaceuticals, Reshma Kewalramani. Thank you ...

Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Mr. Quigley most recently led McKinsey & Company’s Private Capital practice and previously led various Life Sciences practices at the ...

Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025--Phase 1 ...

French audio manufacturer Advance Paris is celebrating its 30th anniversary with the arrival of its Apex series, a premium range of amplifiers and hi-fi components designed to bring together a potent ...

Find out how GDP can help measure the health of a country’s economy Michael Boyle is an experienced financial professional with more than 10 years working with financial planning, derivatives, ...

The stock of niche financial software company Vertex ( VERX 4.13%) didn't get a very good start to the trading week at all.

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

A regional bank named Crescent Financial plans to deploy a generative AI assistant on Vertex AI that will analyze sensitive customer records and chat transcripts. The leadership team must guarantee ...

The pulmonary emphysema market is poised for steady growth driven by rising COPD prevalence, an aging global population, and greater diagnostic awareness. Advances in inhaled therapies, targeted ...